fgfr data cholangiocarcinoma support plan file capmatinib increment
invest summari increas price target
reiter neutral rate on-going esmo
provid updat result cholangiocarcinoma look superior
previous disclos initi data addit late-break present
novarti nv cover report phase ii result inhibitor
capmatinib met-mut advanc non-smal cell lung cancer nsclc patient
note nv receiv world-wide right capmatinib nv report
promis respons rate data compar favor earlier report result
inhibitor includ risk-adjust capmatinib royalti revenu
nvss capmatinib result look promis nsclc patient
geometri phase ii studi evalu single-ag capmatinib
patient met-mut advanc non-smal cell lung cancer nsclc
includ mutat case nsclc morn nv
report orr frontlin patient prior-treat
patient respect assess independ review data
look favor earlier report result inhibitor note pfe
ow cover louis chen crizotinib gener orr
nsclc patient present iaslc phase ib
crizotinib current includ nccn guidelin nsclc patient
gene amplif exon mutat
capmatinib royalti model estim risk-adjust peak capmatinib
sale includ royalti revenu base case
estim patient us/eu nsclc patient
new market build novarti pay royalti futur capmatinib sale
model launch assum potenti file
fgfr inhibitor updat result support plan regulatori file
inci phase ii open-label single-arm studi evalu
advanc cholangiocarcinoma patient primarili patient
transloc fail previou therapi report
confirm orr pr cholangiocarcinoma patient
transloc activ result appreci improv vs last-report
confirm orr patient note longer median month
matur yet report vs last-report month median os
month compani previous guid nda file
disclosur section may found page
rate share neutral price target valuat deriv
dcf-base analysi wherebi probability-adjust pipelin revenu stream
assum discount rate termin growth assumpt
risk neutral rate price target includ unexpect pipelin success
beyond mani program model unexpectedli posit pipelin readout
modul upsid weaker-than-expect jakafi sale could bolster base
busi continu spend growth without correspond pipelin readout
incom statement except ep
product revenu base busi
product revenu pipelin prob adjust
incom tax non-gaap
provis benefit incom tax non-gaap
basic share use comput ep
dilut share use comput ep
balanc sheet
cash equival short-term market secur
prepaid expens current asset
properti plant equip net
intang asset net
current portion long-term debt
total liabil equiti
flow statement
adjust non-oper item
depreci amort
chang
prepaid expens asset
accru expens liabil
purchas available-for-sal secur
proce matur sale market secur
chang
end ce short-term market
dcf valuat
chang work capit
present valu flow
npv
npv termin valu
tv total
incyt corpor wilmington delaware-bas biopharmaceut compani focus discoveri develop
commerci proprietari therapeut first commerci product jakafi ruxolitinib approv unit state
patient intermedi high-risk myelofibrosi patient polycythemia vera inadequ respons
intoler hydroxyurea
